🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. Venetoclax, AZACITIDINE, Venetoclax, azacitidine, Venetoclax, azacitidine

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia in First Remission

    phase 3 small molecule active

    1 trial
  2. Venetoclax, Venetoclax, Cytarabine 100 mg/ml Solution for Injection or Infusion, Matching Placebo for Venetoclax, Venetoclax

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  3. Venetoclax, Venetoclax, Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg film-coated tablets, Venetoclax

    AbbVie Deutschland GmbH & Co. KG

    Chronic Lymphocytic Leukemia

    phase 3 small molecule active

    1 trial
  4. Venetoclax, Venetoclax, Matching Placebo for Venetoclax, Venetoclax, AZACITIDINE

    AbbVie Deutschland GmbH & Co. KG

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial
  5. Venetoclax, Venetoclax, Venetoclax, Vidaza 25 mg/ml powder for suspension for injection, Placebo Venetoclax/ABT-199/Film-coated tablet Oral Use

    AbbVie Deutschland GmbH & Co. KG

    Higher-Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial
  6. Verzenios 150 mg film-coated tablets, EXEMESTANE, IBRANCE 75 mg film-coated tablets, Verzenios 100 mg film-coated tablets, FULVESTRANT, LETROZOLE, Camizestrant, IBRANCE 100 mg film-coated tablets, Saruparib, Verzenios 50 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, RIBOCICLIB, ANASTROZOLE

    AstraZeneca AB

    Advanced Breast Cancer

    phase 3 small molecule active

    1 trial
  7. Verzenios 150 mg film-coated tablets, Kisqali 200 mg film-coated tablets, Faslodex 250 mg solution for injection., IBRANCE 75 mg film-coated tablets, LEUPRORELIN , Verzenios 100 mg film-coated tablets, RO7197597, RIBOCICLIB, IBRANCE 125 mg film-coated tablets, IBRANCE 100 mg film-coated tablets, Verzenios 50 mg film-coated tablets

    Hoffmann-La Roche

    Estrogen receptor (ER)-positive, HER2-negative advanced breast cancer

    phase 3 small molecule active

    1 trial
  8. Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet

    The George Institute

    Hypomethylating agent (HMA) naive myelodysplastic syndromes Myelodysplastic Symdrome (MDS), Myelodysplastic Symdrome (MDS)

    phase 3 small molecule active

    1 trial
  9. Vidaza 25 mg/ml powder for suspension for injection, AG-120/S95031 250mg film-coated tablet, Placebo to Match AG-120 Tablet, 250 mg, is supplied as a film-coated tablet for oral administration.

    The George Institute

    Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation

    phase 3 small molecule active

    1 trial
  10. Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets

    The George Institute

    Acute Myeloid Leukemia, ONCOLOGY

    phase 3 small molecule active

    1 trial
  11. Vigabatrin

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Addiction

    phase 3 small molecule completed

    2 trials
  12. Vildagliptin

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial
  13. Vildagliptin

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial
  14. Vincristine placebo, VINCRISTINE , Polivy 140 mg powder for concentrate for solution for infusion., MabThera 500 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Previously Untreated Diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial
  15. Viread 245 mg film-coated tablets, Viread 123 mg film-coated tablets, Viread 204 mg film-coated tablets, PTM Tenofovir DF, Viread 163 mg film-coated tablets, Viread 33 mg/g granules

    Gilead Sciences Pty Limited

    Hepatitis B Infection

    phase 3 small molecule active

    1 trial
  16. Visilizumab

    The First People's Hospital of Lianyungang

    Immunotherapy

    phase 3 small molecule active

    1 trial
  17. Vocabria 600 mg prolonged-release suspension for injection, REKAMBYS 900 mg prolonged-release suspension for injection

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 3 small molecule active

    1 trial
  18. Vortioxetine

    The University of Hong Kong

    Cannabis Use Disorder

    phase 3 small molecule completed

    1 trial
  19. Vortioxetine tablets

    Takeda

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial
  20. Vyloy 100 mg powder for concentrate for solution for infusion., OXALIPLATIN, FOLINIC ACID, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE, FLUOROURACIL, KEYTRUDA 25 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Vyloy 100 mg powder for concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion., Sodium chloride 0.9% intravenous infusion, ASP8951, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate fo

    Astellas Pharma GmbH

    Gastroesophageal Junction Adenocarcinoma, Gastric Cancer, Gastric Adenocarcinoma

    phase 3 small molecule active

    1 trial
  21. Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Placebo Semaglutide, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Placebo NNC0487 0111 B, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen, NNC0487-0111 B 10144, NNC0487-0111 B 10145, NNC0487-0111 B 10146, NNC0487-0111 B 10141, NNC0487-0111 B 10142, NNC0487-0111 B 10143

    NovoThirteen

    Participants with overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial
  22. Wegovy 2.4 mg solution for injection in pre-filled pen, Rybelsus 14 mg tablets, Clopidogrel Medreg 75 mg filmom obalené tablety, Wegovy 0.25 mg solution for injection in pre-filled pen, Wegovy 0.5 mg solution for injection in pre-filled pen, Wegovy 1 mg solution for injection in pre-filled pen, Rybelsus 7 mg tablets, Wegovy 1.7 mg solution for injection in pre-filled pen, Acetylsalicylic acid Krka 100 mg enterotabletter, Rybelsus 3 mg tablets

    Istituto Gentili S.r.l.

    Diabetes Mellitus, Cardiovascular disease, Overweight (BMI ≥27 kg/m²), Obesity (BMI≥30kg/m2)

    phase 3 small molecule active

    1 trial
  23. XEOMIN 100 unités, poudre pour solution injectable

    Pari Pharma GmbH

    PANCREATIC FISTULA

    phase 3 small molecule active

    1 trial
  24. XEOMIN 200 jednotek prášek pro injekční roztok, XEOMIN, 200 jednostek, proszek do sporządzania roztworu do wstrzykiwań, XEOMEEN 200 eenheden poeder voor oplossing voor injectie, XEOMIN 200 egység por oldatos injekcióhoz, XEOMIN 200 jednotiek prášok na injekčný roztok, XEOMIN 200 unidades polvo para solución inyectable, XEOMEEN 200 unités poudre pour solution injectable, XEOMIN 200 Einheiten Pulver zur Herstellung einer Injektionslösung, XEOMIN 200 unités, poudre pour solution injectable, XEOMIN, 200 unità,

    Merz Pharmaceuticals GmbH

    Lower limb spasticity

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources